Sophiris Bio Files Registration Statement For Proposed IPO
Related Videos
Most Recent
Most Viewed


Sophiris Bio, a biopharmaceutical company developing a treatment for benign prostatic hyperplasia, announced today that it has filed a registration statement on Form S-1 with the SEC relating to a proposed initial US public offering of its common shares on the NASDAQ stock market. The Company has also filed a preliminary short form prospectus with the securities regulatory authorities in British Columbia and Ontario in connection with the proposed offering.